Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (£159 million*).
Verona Pharma plc (LON:VRP) Positive Top-line Data in 4 Week Phase 2b COPD Study.
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function